Get the Stockscreener App
1.43
5.61%
-0.085
Cocrystal Pharma Inc stock is traded at $1.43, with a volume of 22,981.
It is down -5.61% in the last 24 hours and up +7.08% over the past month.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
See More
Previous Close:
$1.515
Open:
$1.45
24h Volume:
22,981
Relative Volume:
1.24
Market Cap:
$14.54M
Revenue:
-
Net Income/Loss:
$-17.93M
P/E Ratio:
-0.8079
EPS:
-1.77
Net Cash Flow:
$-14.28M
1W Performance:
-2.05%
1M Performance:
+7.08%
6M Performance:
-33.49%
1Y Performance:
-24.74%
1-Day Range:
$1.43
$1.66
1-Week Range:
$1.40
$1.66
52-Week Range:
$1.12
$3.26
Cocrystal Pharma Inc Stock (COCP) Company Profile
Name
Cocrystal Pharma Inc
Sector
Industry
Phone
(786) 459-1831
Address
19805 N. CREEK PARKWAY, BOTHELL, WA
Compare COCP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
1.43 | 14.85M | 0 | -17.93M | -14.28M | -1.77 |
|
ONC
Beigene Ltd Adr
|
236.49 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.32 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.24 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.62 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.09 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-20 | Initiated | H.C. Wainwright | Buy |
Cocrystal Pharma Inc Stock (COCP) Latest News
What is Noble Financial’s Estimate for COCP Q2 Earnings? - Defense World
Cocrystal Pharma Reports First Quarter 2025 Financial Results an - GuruFocus
Cocrystal Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cocrystal Pharma (COCP) Advances CDI-988 for Norovirus Treatment - GuruFocus
Cocrystal Pharma (COCP) Advances CDI-988 for Norovirus Treatment | COCP Stock News - GuruFocus
Breakthrough: Cocrystal's Novel Antiviral CDI-988 Demonstrates Superior Activity Against All Major Norovirus Variants - Stock Titan
Cocrystal Pharma (COCP) Projected to Post Earnings on Monday - Defense World
Norovirus Infection Pipeline: 8+ Leading Companies Advancing - openPR.com
Cocrystal Pharma (COCP) Advances Norovirus Drug Candidate CDI-98 - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Hepatitis C Virus Infection Pipeline: 20+ Leading Companies - openPR.com
Cocrystal Pharma (NASDAQ:COCP) Stock Price Up 3.3% – Here’s Why - Defense World
Cocrystal Pharma Advances Norovirus Antiviral Candidate CDI-988 - TipRanks
Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants - The Manila Times
First-Ever Norovirus Treatment Tackles Dominant 2024 Variants: $60B Market Opportunity - Stock Titan
Cocrystal Pharma Presents to Investment Community - TipRanks
Aytu BioPharma Stock Price, Quotes and Forecasts - Benzinga
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference - The Manila Times
Cocrystal Pharma CEO to Reveal Latest Developments at Elite Northwest Biotech Summit - Stock Titan
Addex Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ADXN - Benzinga
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama® - MarketScreener
Strategic Patent Filing Could Transform VTAMA's $233B Market Potential - Stock Titan
OTC Markets Hosts Virtual Investor Presentation with Dr. Sam Lee, Co-CEO & President, and Jim Martin, Co-CEO & CFO, of Cocrystal Pharma, with David Bautz, PhD, Senior Analyst at Zacks SCR - Zacks Small Cap Research
Cocrystal Pharma Approves 2025 Equity Incentive Plan - TipRanks
Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA - openPR.com
Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
COCRYSTAL PHARMA Earnings Preview: Recent $COCP Insider Trading, Hedge Fund Activity, and More - Nasdaq
Q1 Earnings Forecast for COCP Issued By Zacks Small Cap - Defense World
COCP stock touches 52-week low at $1.35 amid market fluctuations By Investing.com - Investing.com South Africa
COCP stock touches 52-week low at $1.35 amid market fluctuations - Investing.com Australia
What is Zacks Small Cap’s Estimate for COCP Q3 Earnings? - Defense World
COCP: Norovirus Challenge Study Planned for 2025… - MSN
Cocrystal Pharma, Inc. SEC 10-K Report - TradingView
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - TradingView
Cocrystal Pharma Pushes Forward with Antiviral Programs Despite $17.5M Loss - Stock Titan
Influenza Pipeline: Advancing Innovation with 120+ Trailblazers Developing Transformative Therapies | DelveInsight - openPR.com
Cocrystal Pharma Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Hepatitis C Virus Infection Pipeline 2025: FDA Updates, Therapy - openPR
Cocrystal Pharma (COCP) to Release Earnings on Thursday - Defense World
Conduit's Triple-Drug Pipeline Shows Promise for Lupus TreatmentMajor R&D Breakthrough - Stock Titan
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - The Manila Times
Bird Flu Vaccine Stocks: 8 Companies Developing H5N1 Vaccines - Investing News Network
Life Sciences Investor Forum Agenda Announced for March 13th - Morningstar
Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga
Cocrystal Pharma to Participate in a Fireside Chat at the - GlobeNewswire
Kaltura to Host 2025 Investor Event - The Manila Times
Direct Access to Cocrystal Pharma Management: Key Details of Upcoming Zacks Analyst Forum - StockTitan
Cocrystal Pharma Inc Stock (COCP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):